(Q44330363)

2 December 2017

title

Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system (English)

1 reference

2 December 2017

0 references

Makino M

1

1 reference

2 December 2017

Kitano Y

2

1 reference

2 December 2017

Komiyama C

3

1 reference

2 December 2017

Hirohashi M

4

1 reference

2 December 2017

Kohno M

5

1 reference

2 December 2017

Moriyama M

6

1 reference

2 December 2017

Takasuna K

7

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

2 December 2017

1 reference

2 December 2017

volume

852

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

482-484

1 reference

Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

The interferons. Mechanisms of action and clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Alpha-interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Prostaglandins do not mediate interferon-alpha effects on mouse behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Is interferon-alpha a neuromodulator?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

A human interferon that crosses the species line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

The biological basis for clinical use of interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Mechanisms of fever induced by recombinant human interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Enhancement of immobility in mouse forced swimming test by treatment with human interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Persistent neurotoxicity of systemically administered interferon-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Naloxone suppresses the rising phase of fever induced by interferon-α

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Depression: a new animal model sensitive to antidepressant treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Clinical toxicity of interferons in cancer patients: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Alpha-interferon inhibits adrenocortical secretion via mu 1-opioid receptors in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

Clinical toxicity of the interferons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2899%2902235-0

10.1016/S0006-8993(99)02235-0

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference